Abstract : Hypertensive diseases of pregnancy (HDP), including preeclampsia and gestational hypertension, profoundly affect mother and fetal health. Increased serum uric acid levels have been associated with negative pregnancy outcomes. This study is to examine the correlation between blood uric acid levels and maternal and perinatal outcomes in women with hypertensive disorders of pregnancy (HDP). To study the association of serum uric acid levels on maternal and perinatal outcome in women with hypertensive disorders of pregnancy. A total of 70 pregnant women diagnosed with hypertensive disorders were enrolled in this cross-sectional study. Serum uric acid levels were measured, and participants were categorized into normal and abnormal uric acid groups. Maternal characteristics, delivery methods, neonatal APGAR scores, and gestational ages were recorded. Statistical analyses were performed to assess the associations between uric acid levels and various outcomes. The abnormal uric acid group had a mean age of 25.0 ± 3.27 years, while the normal group averaged 23.3 ± 3.26 years. Gestational age was significantly shorter in the abnormal group (35.37 ± 2.79 weeks) compared to the normal group (36.76 ± 1.76 weeks, p=0.038). APGAR scores at 1 minute (6.69 ± 1.19 vs. 7.38 ± 1.02, p=0.025) and at 5 minutes (6.59 ± 1.22 vs. 7.24 ± 0.94, p=0.034) were also significantly lower in the abnormal group. This study underscores a notable correlation between increased serum uric acid levels and negative maternal and fetal outcomes in women with hypertensive disorders of pregnancy, stressing the necessity for regular monitoring of uric acid levels to optimize clinical management and improve health outcomes for mothers and infants.